4-Allyl-6-oxa-noribogainalog is a κ-opioid receptor (KOR) agonist of the oxa-ibogalog family related to oxa-noribogaine. It is a highly potent full agonist of the KOR, with an of 1nM and an of 103% in a G protein BRET assay. This is dramatically more potent than oxa-noribogaine or noribogaine at the KOR in the same assay per another study by the same group ( () = 43nM (82%) and 6,100nM (52%), respectively). The drug shows considerable selectivity for activation of the KOR over activation of the μ- and δ-opioid receptors. 4-Allyl-6-oxa-noribogainalog was the most potent KOR agonist in a series of oxa-ibogalog compounds. It was patented by Dalibor Sames and colleagues in 2025, with Sames being a co-founder of Gilgamesh Pharmaceuticals.
See also κ-Opioid receptor agonist Ibogalog § Related compounds List of investigational hallucinogens and entactogens GM-3009
References